AR061070A1 - Preparacion oral que comprende pioglitazona - Google Patents

Preparacion oral que comprende pioglitazona

Info

Publication number
AR061070A1
AR061070A1 ARP070102205A ARP070102205A AR061070A1 AR 061070 A1 AR061070 A1 AR 061070A1 AR P070102205 A ARP070102205 A AR P070102205A AR P070102205 A ARP070102205 A AR P070102205A AR 061070 A1 AR061070 A1 AR 061070A1
Authority
AR
Argentina
Prior art keywords
oral preparation
pioglitazona
understanding
preparation understanding
salt
Prior art date
Application number
ARP070102205A
Other languages
English (en)
Inventor
H Koyama
A Shingaki
K Okochi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38294162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR061070A1 publication Critical patent/AR061070A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

Preparacion oral que enmascara suficientemente el sabor desagradable de la pioglitazona o una sal de la misma. La preparacion oral contiene pioglitazona o una sal de la misma y cloruro de metal alcalino.
ARP070102205A 2006-05-23 2007-05-22 Preparacion oral que comprende pioglitazona AR061070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006143390 2006-05-23

Publications (1)

Publication Number Publication Date
AR061070A1 true AR061070A1 (es) 2008-07-30

Family

ID=38294162

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102205A AR061070A1 (es) 2006-05-23 2007-05-22 Preparacion oral que comprende pioglitazona

Country Status (15)

Country Link
US (1) US8865217B2 (es)
EP (1) EP2019669B1 (es)
JP (1) JP5162475B2 (es)
KR (1) KR20090024181A (es)
CN (2) CN101489538B (es)
AR (1) AR061070A1 (es)
AT (1) ATE534374T1 (es)
CA (1) CA2653786C (es)
CL (1) CL2007001457A1 (es)
ES (1) ES2377839T3 (es)
HK (1) HK1129566A1 (es)
MY (1) MY146781A (es)
PE (1) PE20080180A1 (es)
TW (1) TWI407959B (es)
WO (1) WO2007136129A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20120058205A1 (en) * 2009-03-04 2012-03-08 Walter Howard Peschel Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia
JPWO2010119851A1 (ja) * 2009-04-14 2012-10-22 ライオン株式会社 口腔内崩壊錠
DK2512455T3 (en) * 2009-12-18 2014-03-24 Frieslandcampina Nederland Holding B V Co-treated tablet adjuvant composition, its preparation and use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
JP5630902B2 (ja) * 2010-08-26 2014-11-26 沢井製薬株式会社 ゾルピデム酒石酸塩含有口腔内崩壊錠の製造方法
EP2612657B1 (en) * 2010-08-31 2023-08-09 Kyowa Kirin Co., Ltd. Orodispersible tablet
TW201340998A (zh) * 2012-02-29 2013-10-16 Takeda Pharmaceutical 經口劑
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JP6574556B2 (ja) * 2014-08-27 2019-09-11 日東電工株式会社 口腔内フィルム状基剤及び製剤
CN104174022B (zh) * 2014-09-16 2018-10-16 过冬 一种吡格列酮的苦味抑制剂和包含吡格列酮的口服制剂
JP2018012697A (ja) * 2016-07-11 2018-01-25 大原薬品工業株式会社 口腔内崩壊時間が短縮された、塩を含有する錠剤
US20210386726A1 (en) * 2020-06-11 2021-12-16 Chang Gung University Method for inhibiting coronavirus infection and replication
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2809301B2 (ja) * 1993-12-09 1998-10-08 田辺製薬株式会社 苦味隠蔽された経口投与製剤
CN1059320C (zh) * 1994-04-07 2000-12-13 段永聚 一种无糖型草珊瑚含片
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
WO2003026586A2 (en) * 2001-09-28 2003-04-03 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
JP2003183162A (ja) * 2001-12-17 2003-07-03 Sumitomo Pharmaceut Co Ltd シメチジン経口製剤
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
AU2003213338A1 (en) * 2002-03-14 2003-09-22 Daiichi Suntory Pharma Co., Ltd. Tablet containing pilsicainide hydrochloride (dry)
AU2003230719A1 (en) * 2002-03-21 2003-10-08 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
WO2004026241A2 (en) * 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
KR20070011497A (ko) 2004-05-11 2007-01-24 산텐 세이야꾸 가부시키가이샤 각결막 장해 치료제
KR100843508B1 (ko) * 2004-09-29 2008-07-04 모리나가 뉴교 가부시키가이샤 고혈당 개선용 의약
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
CL2007001194A1 (es) 2006-04-27 2008-01-04 Takeda Pharmaceutical Preparacion farmaceutica solida que comprende particulas que comprenden (i) particulas de nucleo con excipiente y (ii) pioglitazona o una sal de la misma y un polimero soluble en acido, como copolimero de aminoalquil metacrilato e o dietilaminoacetato de polivinilacetal, ambos recubriendo el nucleo

Also Published As

Publication number Publication date
KR20090024181A (ko) 2009-03-06
EP2019669B1 (en) 2011-11-23
HK1129566A1 (en) 2009-12-04
CN101489538B (zh) 2014-01-08
PE20080180A1 (es) 2008-04-22
JP5162475B2 (ja) 2013-03-13
CN103520158A (zh) 2014-01-22
CA2653786A1 (en) 2007-11-29
TWI407959B (zh) 2013-09-11
MY146781A (en) 2012-09-28
EP2019669A1 (en) 2009-02-04
WO2007136129A1 (en) 2007-11-29
JP2009538268A (ja) 2009-11-05
CN101489538A (zh) 2009-07-22
US20100136122A1 (en) 2010-06-03
CA2653786C (en) 2014-09-23
CL2007001457A1 (es) 2008-01-04
US8865217B2 (en) 2014-10-21
CN103520158B (zh) 2016-02-03
ATE534374T1 (de) 2011-12-15
ES2377839T3 (es) 2012-04-02
TW200806332A (en) 2008-02-01

Similar Documents

Publication Publication Date Title
AR061070A1 (es) Preparacion oral que comprende pioglitazona
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
UA94221C2 (en) Lipocalin protein
RS52874B (en) THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
MX2013007236A (es) Composiciones fluidas que comprenden un agente de estructuracion.
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
BRPI0810774A2 (pt) composição de cuidado oral ou cuidado corporal.
EP1962869A4 (en) TREATMENT OF RESPIRATORY DISEASES
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
ECSP11011001A (es) Composición farmacéutica sólida
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
ITTO20050715A1 (it) Calzatura per la prevenzione e la correzione dell'alluce valgo
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
NO20076405L (no) Anvendelse av 24-nor-UDCA
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
HU0500145D0 (en) Composition for the treatment of oral diseases
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
CL2007003315A1 (es) Composicion antimicrobiana sinergica que comprende un complejo de monoetanolamina-cobre (ii) y una 4,5-dicloro-2-n-octil-4-isotiazolin-3-ona.
ES2375436T8 (es) Administración intranasal o por inhalación de virosomas.
EP1951194A4 (en) TREATMENT OF ORAL HYGIENE WITH ANTIMICROBIAL DECAPEPTIDES
AR067498A1 (es) Composicion farmaceutica estable de una sal hidrosoluble de vinorrelbina
UA99093C2 (ru) Применение фенофибрата или его производного для лечения диабетической ретинопатии
AR047175A1 (es) Metodo para el tratamiento de enfermedades pulmonares

Legal Events

Date Code Title Description
FB Suspension of granting procedure